Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

AbbVie (NY:ABBV)

189.26 -2.14 (-1.12%)
Official Closing Price Updated: 7:00 PM EDT, Jul 18, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about AbbVie

< Previous 1 2
...
23 24 25 26 27 28 29 30 31
...
74 75 Next >
Pfizer, Autodesk, AbbVie And More: CNBC's 'Final Trades'
On CNBC’s "Halftime Report Final Trades," Liz Young of BNY Mellon Investment Management named Health Care Select Sector SPDR Fund (NYSE: XLV) 
Via Benzinga
AbbVie, Arch Capital, Gilead Sciences And A Telecom Giant On CNBC's 'Final Trades'
On CNBC’s "Halftime Report Final Trades," Rob Sechan of NewEdge Wealth said Gilead Sciences, Inc. 
Via Benzinga
2 Beaten-Down Stocks to Buy Hand Over Fist This Year
Don't give up on these stocks too soon. 
Via The Motley Fool
Ocular Gene Therapy: Regenxbio Data Shows Consistent Preservation Of Visual Acuity, Retinal Thickness
Regenxbio's latest trial data on ABBV-RGX-314 reveal 80% reduction in injection rate, 50% injection-free, and no intraocular inflammation. 
Via Benzinga
Uber, Abbott Laboratories, Vertex Pharmaceuticals And More On CNBC's 'Final Trades'
On CNBC’s "Halftime Report Final Trades," Jenny Harrington of Gilman Hill Asset Management named Crown Castle Inc. 
Via Benzinga
AbbVie's Options Frenzy: What You Need to Know
Via Benzinga
If You Invested $1000 In This Stock 10 Years Ago, You Would Have $3,300 Today
Via Benzinga
Big Players' Recent Trades in ABBV Options
Via Benzinga
Better Growth Stock: Abbott vs. AbbVie
These healthcare giants also offer investors the promise of increasing passive income. 
Via The Motley Fool
Here's the Average Amount Investors Have in Stocks by Age 40 and Which Stocks I Recommend Today
Curious as to how your portfolio stacks up? Take a look. 
Via The Motley Fool
AbbVie's Strategic Move: ImmunoGen Acquisition Triggers Golden Cross, Yet Valuation Caution Remains
AbbVie Inc (ABBV) stock is up 15% since acquiring ImmunoGen, but past Golden Cross rallies haven't sustained. With high valuation and competition, investors may want to wait for a pullback. 
Via Benzinga
Aesthetics Market Resilience: AbbVie Asserts Widely Used Botox Dominance Amidst Rising Competition
AbbVie Inc's (NYSE: ABBV) unwavering confidence in Botox's resilience within the aesthetics market with a commanding 68% market share remains steadfast. Despite a recent FDA petition addressing... 
Via Benzinga
2 Ultrareliable Dividend Stocks to Buy in 2024 and Hold for at Least a Decade
Strong advantages over the competition could allow these businesses to keep raising their dividend payouts for at least another 10 years. 
Via The Motley Fool
10 Health Care Stocks With Whale Alerts In Today's Session
Via Benzinga
3 Simple Tricks That Every Investor Should Use (but Most Don't)
Having a few tricks up your sleeve can increase your returns over time. 
Via The Motley Fool
Cramer Says This Major Healthcare Stock Is 'Ridiculously Cheap And Doing So Many Great Things'
On CNBC’s "Mad Money Lightning Round," Jim Cramer said he likes Realty Income (NYSE: O) and recommends staying with it. "It’s a very steady story," he noted. 
Via Benzinga
5 Biotech Stocks That Should Be On Investors' Radar As JPMorgan Healthcare Conference Gets Underway Monday
The rebound by biopharma stocks in 2023 and the pickup in M&A news flow makes the 2024 JPMorgan Healthcare conference even more interesting. 
Via Benzinga
3 Boneheaded Investing Mistakes I Pledge Not to Make (Again) in 2024 and Beyond
You should do your best to avoid making similar mistakes too. 
Via The Motley Fool
Is AbbVie Stock a Buy Now?
The company is grappling with losing Humira's patent protection in 2023. 
Via The Motley Fool
Topics Intellectual Property
24 Top Dividend Stocks to Buy and Hold in 2024
These stocks could deliver positive gains in the new year -- but the real money-making opportunities are over the next decade and beyond. 
Via The Motley Fool
3 Magnificent High-Yield Dividend Stocks to Buy in 2024
There's more than meets the eye with all three of these dividend stocks. 
Via The Motley Fool
Eli Lilly, Crispr, Biogen Lead Pharma And Biotech Stocks To Great Expectations In 2024
Between buyouts, obesity drugs and neuroscience progress, biotech stocks stand to gain. 
Via Investor's Business Daily
1 Concerning Trend for AbbVie Investors to Keep an Eye On
Is AbbVie a good stock for dividend investors to own? 
Via The Motley Fool
3 Biotech Stocks Set for Breakthroughs in 2024
With groundbreaking advancements in new medicine and science, 2024 holds a promising future for these biotech stocks. 
Via InvestorPlace
10 Health Care Stocks Whale Activity In Today's Session
Via Benzinga
2 Biotech Stocks You Can Buy and Hold for the Next Decade
The types of innovative drugs these companies develop are always in high demand. 
Via The Motley Fool
3 Top Dividend Growth Stocks to Buy in 2024
Income investors should love these great stocks. 
Via The Motley Fool
The 3 Hottest Dividend Stocks to Watch in 2024
With 2023 in the books and the entirety of 2024 ahead of us, here are compelling dividend stocks to watch for astute investors. 
Via InvestorPlace
3 Top ETFs I'm Planning to Buy Hand Over Fist in 2024, Despite All the Cheap Stocks on My Radar
I'm adding some ETFs to my retirement portfolio in 2024; here are the three I'm starting with. 
Via The Motley Fool
Topics ETFs Retirement
Got $1,500? You Can Confidently Add These 3 Stocks to Your Portfolio
Getting going on investing is a terrific way to start 2024. 
Via The Motley Fool
< Previous 1 2
...
23 24 25 26 27 28 29 30 31
...
74 75 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.